Why time still matters in acute stroke care

Treatment windows in acute stroke are wider than they used to be. The 2026 guideline from the American Heart Association and American Stroke Association supports treating selected patients well beyond the intervals that once defined eligibility, using imaging rather than the clock to decide. It would be easy to read that as the retirement of "time is brain."

That reading is wrong, and the reason it is wrong is worth understanding, because the same error appears whenever a field widens a criterion. A wider window describes who may still benefit. It is not a finding that delay became harmless. Within the intervals that have been studied, shorter time from symptom onset to treatment remains associated with better functional outcomes.

The field did not stop asking how long it has been. It added a second question: how much brain is still salvageable. This article is about why those are different questions, and why the answer to one never cancels the other. It is educational and not a substitute for personal medical advice.

What happens to brain tissue during an ischemic stroke?

An ischemic stroke occurs when blood flow to part of the brain is blocked, usually by a clot. It is distinct from a hemorrhagic stroke, in which a vessel bleeds. The two require opposite treatments, which is why imaging comes before any clot-dissolving drug is given.

When flow stops, the affected territory does not fail all at once. Researchers describe two zones. The core is tissue that has already infarcted, meaning it has died and will not recover. The penumbra is tissue that is underperfused and not functioning, but still structurally alive and potentially salvageable if flow is restored.

The penumbra is the entire target of acute treatment. Nothing done in the emergency department recovers the core.

What matters for the argument here is that the penumbra converts to core at different speeds in different people. The main reason is collateral circulation, the alternative vessels that partially supply a territory when the main artery is blocked. A person with robust collaterals can hold viable penumbra for many hours. A person with poor collaterals may lose it quickly.

This is the biological fact underneath the whole debate. A fixed clock was always an approximation of a process that runs at a variable rate. It was a reasonable approximation, because time was measurable at the bedside and tissue viability was not.

How did the treatment window get wider?

Two acute treatments are at issue. Intravenous thrombolysis is the delivery of a clot-dissolving drug through a vein. Endovascular thrombectomy is the mechanical removal of a clot through a catheter threaded to the blocked artery.

The 2026 AHA/ASA guideline for the early management of acute ischemic stroke, published January 26, 2026, sets out several positions relevant here. According to the American Heart Association's summary of the guideline, it endorses either alteplase or tenecteplase within the 4.5-hour thrombolytic window, and supports rapid treatment of eligible patients with disabling deficits within that window without advanced imaging selection, regardless of score on the National Institutes of Health Stroke Scale (NIHSS), a standardized measure of stroke severity.

Beyond that window, selection changes. The guideline supports extended-window thrombolysis for selected patients with stroke of unknown onset, or 4.5 to 9 hours from onset, using advanced imaging criteria such as diffusion-weighted imaging and fluid-attenuated inversion recovery mismatch, or perfusion-based mismatch. Those imaging patterns are, in effect, an attempt to see the penumbra directly rather than infer it from elapsed time.

For thrombectomy, the guideline gives a strong recommendation in patients with basilar artery occlusion presenting within 24 hours of symptom onset with an NIHSS score of 10 or higher.

Note what changed conceptually. Imaging replaced the clock as the selection tool for patients presenting late. It did not replace the clock as a prognostic factor. Those are two separate roles, and conflating them is the error this article is about.

Why is eligibility not the same question as benefit?

This is the methodological heart of the matter, and it generalizes far beyond stroke.

An inclusion window answers a question about a boundary: who was enrolled and studied. An analysis of outcome against treatment time, among people who were all treated, answers a different question: how the size of the benefit varies across that interval. A trial can widen the first without saying anything at all about the second.

The evidence on the second question is direct. A meta-analysis of individual patient data, meaning an analysis that pools the original patient-level records from multiple trials rather than their published summaries, examined 6,756 patients across nine randomized trials of intravenous alteplase. Emberson and colleagues reported in The Lancet in 2014 that the odds of a good outcome, defined as a score of 0 to 1 on the modified Rankin Scale, an ordinal measure of disability after stroke running from 0 for no symptoms to 6 for death, were higher with alteplase and that the size of that advantage fell as treatment was delayed: an odds ratio of 1.75 (95% confidence interval 1.35 to 2.27) when treatment began within 3 hours, 1.26 (1.05 to 1.51) between 3 and 4.5 hours, and 1.15 (0.95 to 1.40) beyond 4.5 hours. The authors concluded that alteplase significantly improves the overall odds of a good stroke outcome when delivered within 4.5 hours of onset, with earlier treatment associated with larger proportional benefits.

The pattern holds for thrombectomy. Saver and colleagues, publishing in JAMA in 2016, pooled 1,287 patients from five randomized trials of endovascular thrombectomy for large-vessel occlusion. The common odds ratio for less disability at three months was 2.79 (1.96 to 3.98) at 3 hours from onset, 1.98 (1.30 to 3.00) at 6 hours, and 1.57 (0.86 to 2.88) at 8 hours, with benefit retaining statistical significance through roughly 7.3 hours. Among the subset of patients who achieved substantial reperfusion, each additional hour of delay was associated with a less favorable degree of disability.

Two honest limitations belong with those numbers.

First, these are associations, not demonstrations that delay itself caused the difference. Patients who present late and are still treated are a selected group. They often have better collateral circulation, which is precisely why they still had salvageable tissue to treat. That same characteristic independently predicts better recovery. So part of any observed time gradient reflects who arrives when, not only what the clock did to them. The direction of the effect is consistent and biologically coherent, but the magnitude should be read with that caveat attached.

Second, the estimates above come from trials with their own enrollment criteria, conducted before the more recent imaging-selected evidence that supports the wider windows now recommended. They describe the gradient observed within those trials. They are not a verdict on eligibility beyond them.

The transferable lesson is this. Widening an inclusion criterion is a statement about where a boundary sits. It is never, by itself, a statement that the gradient inside the boundary disappeared. Any time a headline reports that a treatment window has been extended, the two claims are worth separating deliberately, because the reporting rarely does it.

Why does the guideline change where the ambulance goes?

Because the treatment a patient needs may not be available at the nearest hospital.

Thrombolysis can be given at many hospitals. Thrombectomy requires a facility with the equipment and personnel to perform it. Routing a patient to the closest hospital can therefore mean a second transfer, and transfers take time during exactly the interval when the gradient described above is steepest.

The 2026 guideline addresses this directly. Per the American Heart Association's summary, it endorses consideration of the characteristics of the local system of care, and direct transport to the closest thrombectomy-capable hospital in the absence of well-functioning systems with rapid interhospital transfer processes.

That conditional phrasing is doing real work and should not be flattened. Bypassing a nearer hospital is not free. It lengthens the time to any treatment in order to shorten the time to one specific treatment, and whether that trade favors the patient depends on local geography, transfer efficiency, and capability. This is a systems-of-care question rather than a simple rule, and it is where access to timely stroke treatment becomes a research question about population-level disparities rather than a logistical footnote.

What should a careful reader take from a wider window?

The two statements sit together without contradiction. More people are now candidates for acute stroke treatment than were candidates a decade ago, because imaging can identify salvageable tissue that the clock alone would have written off. And among those candidates, earlier treatment remains associated with better outcomes.

Two symmetrical misreadings are worth resisting. The first is that nothing has changed, which ignores a real expansion in who can be helped. The second is that the clock stopped mattering, which is not what any of the underlying evidence shows.

More broadly, this is a useful case for reading any guideline revision carefully. Guidelines answer questions about eligibility, evidence quality, and systems of care simultaneously, and a change to one of those is routinely reported as though it were a change to all three.

Further reading on stroke outcomes research is available on this site, along with the peer-reviewed publications behind it.